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Abstract
Homocystinuria is a metabolic disorder caused by a  
deficiency of cystathionine β-synthase (CBS). The  
major clinical symptoms of this disease are mental 
retardation, lens dislocation, vascular disease with  
life-threatening thromboembolisms, and skeletal 
deformities. The major treatments for CBS deficiency  
include pharmacologic doses of pyridoxine or 
dietary restriction of methionine. There is currently  
no effective long-term treatment to lower the elevated  
plasma levels of homocysteine. However, gene 
therapy could be an effective novel approach for the  
treatment of homocystinuria. A recombinant adeno- 
associated virus vector carrying human CBS cDNA 
(rAAV-hCBS) was constructed and administered to  
CBS-/- mice by intramuscular (IM) and intraperitoneal 
(IP) injections. Serum homocysteine concentrations 
significantly decreased in treated mice compared  
with age-matched controls two weeks after treat-
ment. The treated CBS-/- mice had life spans 3-7 days 
longer compared with untreated CBS-/- mice. In CBS-/- 
mice treated with rAAV-hCBS via IP injection, the  
vector was detected in all organs examined including  
liver, spleen, and kidney, and CBS gene expression  
was observed by immunohistochemical staining in  
the liver. These results indicate the efficacy of gene 
delivery and demonstrate the possibility of gene 
therapy mediated by AAV gene transfer in this mouse  
model of homocystinuria.
Keywords: cystathionine -synthase; dependovirus; 
gene therapy; homocysteine; homocystinuria; mouse
Introduction
Homocystinuria (MIN 236200) is a metabolic disor-
der inherited by an autosomal recessive pattern cau-
sed by a deficiency of cystathionine -synthase 
(CBS; EC 4.2.1.22). Major clinical symptoms include 
mental retardation, lens dislocation, vascular dise-
ase with life-threatening thromboembolisms, and ske-
letal deformities (Mudd et al., 1985; 2001). CBS is a 
pyridoxal-5-phosphate-dependent enzyme, which con-
verts homocysteine to cystathionine in the transsul-
furation pathway. The enzyme is comprised of 551 
amino acids and forms a homotetramer of 63 kDa 
subunits. The structure of the enzyme consists of a 
catalytic domain of 409 amino acids located in the 
N-terminal, and a regulatory domain of 142 amino 
acids located in the C-terminal (Kery et al., 1998; 
Shan and Kruger, 1998). Interestingly, deletion of the 
C-terminal regulatory region, or specific point mu-
tations within this region, can functionally suppress 
the phenotype of several CBS mutant alleles iden-
tified in homocystinuria when expressed in yeast 
(Shan and Kruger, 1998; Shan et al., 2001).
    A lack of CBS activity causes the accumulation of 
homocysteine, the export of excess homocysteine 
from the cell, and results in hyperhomocysteinemia, 
which may be toxic to cells. Moreover, it perturbs the 
methylation cycle, such as the intracellular accumu-
lation of S-adenosyl homocysteine, which has con-
sequences for cell metabolism (Boers et al., 1985). 
Elevated homocysteine levels are a potential risk 
factor for cardiovascular disease (Guba et al., 1996; 
Robert et al., 2003b), and several studies have 
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shown that homocysteine induces endothelial dys-
function and injury (Weiss et al., 2002; Denis et al., 
2003).
    The major treatments for CBS deficiency include 
administration of pyridoxine, a diet low in methio-
nine, a diet high in cysteine, and dietary sup-
plementation with betaine. Homocysteine-reducing 
therapies delay the development of clinical symp-
toms and markedly reduce the risk of vascular events 
(Wilcken et al., 1997; Schwahn et al., 2004), sug-
gesting that homocysteine is involved in the patho-
genesis of thromboembolism. However, approxima-
tely 50% of patients are biochemically responsive to 
pharmacological doses of pyridoxine and the treat-
ment must be continued throughout the individual’s 
life (Mudd et al., 1985). A multi-center study that con-
ducted long-term treatment to lower the markedly 
elevated plasma levels of homocysteine in patients 
showed unsatisfactory results (Yap et al., 2001). 
Most treated patients (even pyridoxine-responsive 
cases) have total homocysteine levels well above 
normal. These levels were several times higher in 
patients with CBS deficiency compared with the 
means for the respective normal population of each 
center (Yap et al., 2001). Therefore, effective and 
long-term treatments to reduce homocysteine levels 
in severe types of homocystinuria are needed, and 
gene therapy, which has not yet been studied, could 
provide a novel approach to treating the disease.
    In this study, a recombinant adeno-associated virus 
(rAAV) vector was used as the gene delivery vehicle. 
rAAV is a promising vector for gene therapy because 
of its stability in the long-term expression of trans-
gene products that have relatively weak immune 
responses (Snyder et al., 1997; Halbert et al., 2000). 
Numerous in vivo studies have demonstrated that 
recombinant AAV-2 vectors can efficiently transduce 
many tissues and lead to stable gene expression 
(Bueler et al., 1999; Snyder, 1999). AAV vectors have 
been widely used in gene therapy studies in inhe-
rited diseases such as hemophilia B (Kay et al., 
2000; Manno et al., 2003), cystic fibrosis (CF) (Flotte 
et al., 2003), and Fabry disease (Takahashi et al., 
2002) with promising results.
    In this study, the efficacy of gene therapy using 
rAAV vectors in a murine model for homocystinuria, 
the homozygotes (CBS-/-) and heterozygotes (CBS+/-), 
has been studied.
Materials and Methods
Cloning of human CBS cDNA
To synthesize human CBS (hCBS) cDNA, liver RNA 
was isolated from a human hepatoma cell line 
(HepG2) and RT PCR was carried out as per a 
general protocol. Full length (hCBSfull) cDNA of the 
CBS gene and mutated cDNA of the CBS gene, 
which included a point mutation and deletion of the 
regulatory domain of the CBS gene (hCBSdel), were 
amplified and cloned into a pGEM-T Easy Vector 
(Promega, Madison, WI). Verification of the identity 
of the hCBS cDNA was performed by DNA sequen-
cing. The nucleotide sequences were referred to the 
NCBI GenBank (accession no. NM_000071).
Production of rAAV-hCBS vectors
The parent plasmid pAAV-EF-pL-WPRE-BGHpoly(A), 
based on AAV type 2, was created as previously 
described (Davidson et al., 2000) with minor modifi-
cations. Large-scale production of the rAAV-EF-CBS 
vector was carried out in an adenovirus-free system 
by triple transfection with the vector plasmid and 
helper plasmids (Davidson et al., 2000). The rAAV- 
hCBS vector was prepared and isolated by CsCl 
density gradient ultracentrifugation. The titer of rAAV- 
hCBS genomic DNA was determined by real-time 
quantitative PCR using the ABI7700 (Perkin-Elmer/ 
Applied Biosystems, Foster City, CA), in which the 
signal from aliquots of a test material was compared 
with a standard signal generated using the linearized 
pAAV-EF-hCBS-WPRE-BGHpoly(A) plasmid.
Cell lines
A human embryonic kidney cell line, 293T, a human 
hepatoma cell line, HepG2, and the NIH3T3 cell line, 
were propagated in Dulbecco’s Modified Eagle’s 
Medium supplemented with heat-inactivated 10% 
fetal bovine serum and antibiotics.
Animals
All animal experiments were carried out in accor-
dance with our institutional guidelines. C57BL/6J- 
Cbstm1Unc mice were obtained from the Jackson 
Laboratory (Maine). The heterozygous CBS-deficient 
mice (CBS+/-) were bred to obtain homozygous 
CBS-deficient mice (CBS-/-). Most homozygous 
CBS-/- mice die within two weeks after birth when fed 
a standard laboratory diet. In order to select homo-
zygous mice, genotypes for the targeted CBS allele 
were identified four days after birth with genomic 
DNA obtained from tail biopsies as described (Wa-
tanabe et al., 1995). Five- or six-day-old CBS-/- mice 
were used for in vivo gene transfer. Culture medium 
(50-100 l) containing 2 × 1012 rAAV-hCBSfull or 
rAAV-hCBSdel was slowly delivered to the mice 
using an insulin syringe with a 29-gauge needle by 
intramuscular (IM) or intraperitoneal (IP) injection. 
Animals were killed and examined two weeks after 
rAAV-CBS administration.
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    Ten-week-old CBS+/- mice were anesthetized with 
ketamin/xylazine and injected with 1 × 1012 viral par-
ticles of rAAV-hCBSfull or rAAV-hCBSdel into the 
hepatic portal vein. Animals were killed and analy-
zed two, six, and 12 weeks after rAAV-CBS adminis-
tration. The liver, kidney, heart, intestine, peritoneum 
and lungs were isolated from each rAAV-injected 
CBS-/- and CBS+/- mouse, along with age-matched 
wild-type controls and untreated CBS-/- and CBS+/- 
mice, for further analysis.
Plasma homocysteine assay
Blood samples were collected in tubes containing 
0.5 M EDTA and plasma homocysteine levels were 
determined by HPLC (HPLC/fluorescence detector, 
Bio-Rad 2800 series) with fluorometric detection 
according to a previously described protocol (Araki 
and Sako, 1987). The method involved deproteini-
zation of a small volume of plasma (50 l) followed 
by HPLC analysis and homocysteine levels were 
determined using a HPLC reagent kit (Bio-Rad, CA).
CBS enzyme assay
The CBS enzyme assay was performed according to 
previously described methods (Kraus, 1987). The 
enzyme activity was assayed by measuring the 
production of [14C]-cystathionine from [14C]serine. 
The reaction was initiated by addition of L-homo-
cysteine (final concentration, 10 mM) and incubated 
for 1 h at 37oC in the presence or absence of 1 mM 
S-adenosylmethionine (SAM). The assay was termi-
nated by cooling the sample to 0oC in an ice bath. 
Samples were applied to a thin layer chromatogra-
phy (TLC) system (TLC Silica Gel 60 plates, Merck, 
Darmstadt, Germany) and developed in butanol/ace-
tic acid/distilled water (60:15:25, v/v/v) at room tem-
perature. The [14C]-cystathionine was separated from 
[14C]-serine by ascending TLC. Quantification of ra-
dioactivity of [14C]-serine and converted [14C]-cysta-
thionine was done using the ImageQuant, after visu-
alization with a PhosphoImager (Molecular Dynamics, 
Sunnyvale).
Western blot analysis of hCBS
Protein extracts were isolated from transduced 
NIH3T3 cells and HepG2 cells. Protein extracts (30 
g per lane) were separated by SDS/PAGE using 
10% polyacrylamide gels and transferred onto 
nitrocellulose membrane (Life Technologies, Gaither-
sburg, MD). The nitrocellulose membrane was hybri-
dized with a 1:7,500 dilution of rabbit antibody aga-
inst human CBS and subsequently with a horse-
radish peroxidase-conjugated anti-rabbit antibody (Santa 
Cruz Biotechnology, Santa Cruz, CA). The signals 
were then visualized using an ECL-Plus enhanced 
chemiluminescence detection system (Santa Cruz 
Biotechnology, Santa Cruz, CA).
Tissue distribution of recombinant viral vectors
In order to assay the distribution of recombinant viral 
vectors in different organs, RT PCR was performed. 
Total RNA was isolated using TRI Reagent (Mole-
cular Research Center, Cincinnati, OH). The RT-PCR 
reaction was carried out with 100 pmol/ l of random 
primer (Takara, Japan). For detection of specific 
human cystathionine -synthase sequences, the fol-
lowing primers were used at a concentration of 25 
pmol: forward primer, 5'-CAAGTGTGAGTTCTTCAA-
CGCG-3'; reverse primer, 5'-GGGATGAAGTCGTA-
GCCGATC-3'. These primers amplified a 615 bp 
product. Primers to mouse GAPDH were used as an 
internal control and amplified a 530 bp product 
(forward primer, 5'-CCCACACTGTGCCCATCTAC-3'; 
reverse primer, 5'-AGTACTTGCGCTCAGGAGGA-3'). 
After PCR amplification, products were analyzed on 
1% agarose gels and visualized with ethidium 
bromide.
Histological examination
Livers were removed from mice administered rAAV- 
hCBS and age-matched control mice. The liver tis-
sues were fixed in 4% formaldehyde, embedded in 
paraffin, and sectioned. Paraffin sections were stained 
with hematoxylin and eosin, and examined by a spe-
cialized pathologist.
Immunohistochemistry
Sections of the liver were incubated with anti-CBS 
antibody (1:2,000 dilution) at 4oC for overnight. Anti- 
rabbit IgG was used as secondary antibody in which 
sections were incubated for 1 h at room temperature. 
The immunoreactivity was visualized by treating the 
slides with DAB plus substrate chromogen reagent 
for 20 sec at room temperature. Tissues were counter-
stained with hematoxylin, dehydrated through a gra-
ded series of alcohol, cleared in xylene, and cover-
slipped.
Statistical analysis
The statistical significance of differences between 
groups was determined using Student’s t test. The 
data are presented as mean ± SD. A P value of less 
than 0.05 was considered significant.
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Results
Construction of transgene
The transgene, hCBS cDNA, was driven by a human 
elongation factor 1-  promoter endowed with further 
stability by the woodchuck hepatitis virus posttrans-
criptional regulatory element, WPRE, and the polya-
denylation site was provided by the BGH polyA . The 
full-length hCBS cDNA encodes for 551 amino acids. 
The mutant hCBS cDNAs constructed in the C-ter-
minal region of the gene included a deletion in the 
C-terminal of 420-551 (419 amino acids plus the 
stop codon) and a point mutation (Q451G).
Expression of rAAV-hCBS after in vitro transduction
Since the CBS gene is not expressed in NIH3T3 
cells, these cells were used as a negative control 
cell line for the in vitro assay. NIH3T3 cells were 
infected at an MOI of 5,000 and 20,000 at a cell 
density of 60%. Two days after infection, protein was 
isolated from rAAV-hCBS transduced and untrans-
duced cells for analysis of enzyme expression and 
activity (Figure 1). CBS expression was observed in 
rAAV-hCBS transduced cells, and no CBS expres-
sion was observed in untransduced controls (Figure 
1A). A band of 63 kDa was observed in HepG2 
positive control cells and transduced cells using a 
monospecific anti-CBS antibody. The enzyme acti-
vity assay measuring the conversion rate of [14C]- 
serine to [14C]-cystathionine also showed results con-
sistent with the western blot analysis (Figure 1). 
These in vitro studies confirmed that the rAAV-EF1 - 
hCBS vector was capable of delivering a functional 
gene to the cells. Enzyme activity was compared 
between full-length and C-terminal mutant forms of 
the CBS gene in the presence and absence of 
S-adenosyl-L-methionine (AdoMet). The wild-type CBS 
gene showed the same enzyme activity as the 
mutant forms of Q451G in the absence of AdoMet. 
Figure 1. Western blot and enzyme assay of NIH3T3 cells transduced with rAAV-hCBS. Analysis was per-
formed two days after transduction with rAAV-hCBS at MOI of 5,000 and 20,000. (A) Cell extracts were sepa-
rated by 10% SDS-PAGE, blotted onto a nitrocellulose membrane and probed with human CBS antibody. Goat 
anti-rabbit IgG was used as the secondary antibody. Bands of 63 kDa and 49 kDa were detected in immuno-
blots of cells transduced with rAAV-hCBS (lanes 3-8). These bands were not visible in untransduced cells (lane 
2). The 63-kDa-band is present in the positive control HepG2 cells (lane 1). (B) Each cell extract was assayed 
for CBS activity with and without 100 M S-adenosylmethionine (SAM) as described. CBS enzyme activity was 
examined by thin layer chromatography. Full: wild-type CBS; Full*: Q451G mutation in C-terminal region; 3'del: 
deletion of C-terminal region (420-551). Values are presented as the mean ± SD.
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In contrast, the 3'-deleted protein showed the same 
or slightly lowered enzyme activity than the wild-type 
CBS protein. In HepG2 cell line, the enzyme activity 
was increased for 1.5 times in the presence of Ado-
Met. It was similar in full-length and C-terminal mutant 
forms of the CBS gene. The wild-type CBS gene 
showed increased enzyme activity of 1.5 to 2 times 
in the presence of AdoMet. The C-terminal deletion 
form of the CBS gene resulted in the absence of 
stimulatory effect of AdoMet (Figure 1B). 
Elongation of life spans
Homozygous mutants suffered from severe growth 
retardation, such as delayed eye opening and the 
majority of them died within five weeks after birth 
with low body weight (Watanabe et al., 1995). The 
average life span of untreated CBS-/- mice was about 
15.6 ± 1.78 days. After CBS-/- mice were injected with 
rAAV-hCBSfull, the life span lengthened by appro-
ximately 3-7 days. Intraperitoneal injection of rAAV- 
hCBSfull was a more effective method of gene 
delivery compared with IM injection, and mice given 
IP injections showed an elongated life span of 21.4
± 2.94 days (Figure 2).
Homocysteine levels in plasma
Plasma homocysteine levels of homozygotes were 
approximately 40 times higher than those of age- 
matched control littermates at 2 weeks after birth. 
The homocysteine levels of heterozygotes were 
about two times higher compared with wild-type 
mice (Figure 3). Plasma homocysteine levels were 
measured two weeks after delivery of rAAV-hCBS. 
The basal plasma homocysteine level of untreated 
CBS-/- mice was 401.66 ± 38.67 M. At two weeks 
after injection, plasma homocysteine levels in mice 
infused with viral vectors rAAV-hCBSfull and rAAV- 
hCBSdel (2 × 1012 viral particles) decreased to 241.83
± 54.58 M and 301.6 ± 63.97 M, respectively 
(Figure 3). The homocysteine concentration in the 
treated CBS-/- mice decreased to 40% of the levels 
observed in untreated CBS-/- mice.
Distribution of recombinant virus in various tissues
RNA was extracted from various organs two weeks 
after an IP injection with viral vectors rAAV-hCBSfull 
and rAAV-hCBSdel and analyzed for tissue distribu-
tion of the viral transgene vector. The hCBS-specific 
band was identified in treated mice. Recombinant 
viral vectors were distributed in major organs such 
as heart, lungs, liver, intestine, peritoneum, and 
kidneys (Figure 4).
Figure 2. Survival rates of CBS-/- mice administered rAAV-hCBSfull via different routes. IM, intra muscular injection; IP, intraperitoneal injection.
Figure 3. Plasma homocysteine concentrations in CBS-/- mice after the 
administration of rAAV-hCBS (2 × 1012 viral particles) via IP injection. 
Animals were killed after two weeks. Values are presented as means
± SD (n = 3).
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Histological and immunohistochemical study
Most homozygotes showed severe growth retarda-
tion and their eyes were not opened entirely. The 
livers from mutant homozygotes had the paler surface 
color in contrast to the reddish-brown color observed 
in those of heterozygotes and wild-type mice. Fat 
droplets were prominent in the liver of CBS-/- mice 
and the cytoplasm was filled with microvesicular lipid 
droplets (Figure 5A). In rAAV-injected mice, the gross 
color of the liver was somewhat changed to reddish- 
brown and microvesicular fat droplets reduced on 
histological examination (Figure 5B and C). However, 
many macrovesicular fat changes were observed in 
the treated mice. Immunohistochemical staining with 
anti-hCBS antibody showed that CBS protein was 
present in the cytoplasm of hepatocytes in mice 
treated with rAAV-hCBS. Mice administered rAAV- 
hCBSfull showed more enzyme protein compared 
with mice administered rAAV-hCBSdel (Figure 5). 
This result was consistent with serum homocysteine 
concentration.
Figure 4. Analysis of tissue distribution of rAAV-hCBSfull and rAAV- hCBSdel after IP injection in CBS-/- mice. RT PCR was performed to analyze the 
distribution of the rAAV vector in different tissues. The vector-specific fragment was amplified from all tissues examined in mice injected with 
rAAV-hCBS, whereas no signal was obtained in untreated mice. The mouse GAPDH gene was used as an internal control. +, wild-type mouse; -, un-
treated CBS-/- mouse.
Figure 5. Histological examination (A-C) and immunohistochemical staining (D-F) of the liver after administration of rAAV-hCBS from untreated CBS-/- 
mice (A, D), and CBS-/- mice injected with rAAV-hCBSfull (B, E) and rAAV-hCBSdel (C, F). An increased amount of CBS protein was observed by im-
munohistochemical staining in mice injected with rAAV-hCBS (n = 3).
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Administration of rAAV-CBS into CBS+/- mice
Since homozygous CBS-deficient mice exhibit growth 
retardation, hepatic dysfunction, and shortened life 
spans, they may have limitations as a model for 
studying gene therapy. The heterozygous mice grew 
normally and were relatively healthy, even though 
they had an approximate 50% reduction in CBS 
mRNA and CBS enzyme activity in the liver and 
twice the normal levels of plasma homocysteine 
(Watanabe et al., 1995). In this study, the efficacy of 
gene transfer with rAAV-CBS was tested in CBS+/- 
mice. Homocysteine concentrations in plasma were 
measured at two, six and 12 weeks after injection. 
The CBS+/- mice showed plasma homocysteine 
levels two times higher compared with CBS+/+ mice 
(11.3 ± 0.95 M vs. 22.6 ± 1.8 M) two weeks after 
birth. Plasma homocysteine levels decreased with 
age in both wild-type and heterozygous mice, and 
homocysteine concentrations between wild-type and 
heterozygous mice were not significantly different at 
12, 16 and 22 weeks (7.8 M, 4.8 M, 5.8 M vs. 7.4 
M, 6.3 M, 7.7 M, respectively). Plasma homocy-
steine levels in heterozygous mice injected with 
rAAV-hCBSfull and rAAV-hCBSdel at 12, 16 and 22 
weeks were 6.4 M, 9 M, 8.3 M vs. 9.7 M, 8.7 M, 
6.1 M, respectively. Plasma homocysteine levels in 
heterozygous mice did not decrease after gene 
transfer (Figure 6). There was also no significant 
increase in enzyme activity in mice injected with 
rAAV-hCBSfull and rAAV-hCBSdel (data not shown).
Discussion
There are currently three recognized modalities for 
the treatment of homocystinuria caused by CBS 
deficiency. In the pyridoxine responsive group, only 
pyridoxine administration in combination with folic 
acid and/or vitamin B12 (Wilcken et al., 1997) is 
an effective treatment. The administration of pyri-
doxine putatively stimulates residual CBS activity. 
For the pyridoxine non-responsive group, a methi-
onine-restricted, cysteine-supplemented dietary the-
rapy (Robert et al., 2003a) should be employed even 
though its effectiveness is restricted. Pyridoxine, 
folic acid and vitamin B12 have continued to be 
administered in pyridoxine non-responders beca-
use they are cofactors of methionine metabolism. 
Additionally, betaine, a methyl donor that remethy-
lates homocysteine to methionine, has been used 
as an adjunct to treatment (Wilcken et al., 1985). 
Early diagnosis and proper treatment is very impor-
tant, especially during the newborn period or even 
later in infancy, to prevent or greatly reduce the 
severity of complications. However, lifelong dietary 
control is difficult in practice and novel approa-
ches that are effective at reducing homocysteine 
levels in the long-term are needed. In this study, 
rAAV has been studied as a CBS gene-transfer 
vector to reduce excess homocysteine in a mouse 
model of homocystinuria.
    Human CBS is predominantly expressed in 
the liver and the liver is the target organ for the 
treatment of other metabolic diseases. To deliver 
therapeutic genes, viral vectors are considered the 
most effective tools for efficient gene transfer to 
the liver in vivo and rAAV vectors represent a very 
promising tool for this process (Buning et al., 
2003). Many studies have shown that AAV vectors 
can transduce foreign genes for long-term expres-
sion in animal models (Jung et al., 2001; Xu et 
al., 2001; Oh et al., 2004).
    In the present study, improvements in CBS en-
zyme expression and prolongation of life span after 
AAV-mediated transduction into CBS-/- mice has 
been demonstrated. However, the long-term effect of 
gene transfer could not be observed because of the 
following reasons. Firstly, an IP injection of rAAV 
vectors cannot deliver the normal CBS gene into the 
liver at sufficient levels to overcome the clinical 
features of homocystinuria. The viral vector had to 
be injected intraperitoneally because the homozy-
gous mice were too small to inject the vector via the 
hepatic portal vein. Secondly, the mouse model used 
in this study was not suitable for gene therapy 
experiments because homozygous null alleles of the 
CBS gene in mice are lethal in contrast to human. 
CBS-/- mice showed severe growth retardation and 
Figure 6. Plasma homocysteine levels in CBS+/- mice administered 
rAAV-hCBS via the portal vein. CBS+/- mice were administered with 1
× 1012 viral particles and killed at two, six and 12 weeks after 
injection. WT, wild-type mice (CBS+/+); UT, untreated heterozygous 
mice (CBS+/-); Full, heterozygous mice injected with rAAV-hCBSfull; 
Del, heterozygous mice injected with rAAV-hCBSdel. Values are pre-
sented as the mean ± SD (n = 3).
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most of them died within two weeks after birth. Plas-
ma homocysteine levels in CBS-/- mice were higher 
in this study compared with previous studies, 401.66 
± 38.67 M vs. 205 ± 86 M, respectively (Robert 
et al., 2003a). This difference in homocysteine levels 
may be caused by a standard laboratory diet given 
in this study, instead of a special diet, in order to 
avoid the effect of diet therapy. CBS-/- mice are 
usually fed a standard A04 rodent chow, which is 
rich in choline chloride that is necessary for their 
survival (Robert et al., 2003a). Betaine-homocysteine 
methyltransferase in liver and kidney cells can 
transfer a methyl group to methionine from betaine, 
the oxidized form of choline, providing a secondary 
pathway for homocysteine remethylation (Finkel-
stein, 2000). 
    For a long-term therapeutic effect, new mouse 
models for homocystinuria induced by various types 
of mutation in the CBS gene will be preferentially 
needed to conduct gene therapy experiments on this 
disease. In humans, most pathogenic mutations are 
missense mutations within the CBS gene (Kraus et 
al., 1999). Further experiments remain to be evalu-
ated; including potentials of alternative AAV serotypes, 
not AAV2 and the efficacy of rAAV delivered pren-
atally. Finally, the development of new therapeutics 
strategies will be necessary to correct homocystin-
uria patients.
    The C-terminal of the human CBS gene is known 
to be a regulatory domain, consisting of approximately 
140 amino acid residues. The allosteric activator, 
AdoMet, increases CBS activity by about three times 
and probably binds to the C-terminal regulatory 
domain (Shan et al., 2001). The C-terminal regula-
tory domain also encompasses the previously defined 
CBS domain, which is conserved in a wide range of 
otherwise unrelated proteins (Bateman, 1997). Muta-
tions in this domain can constitutively activate the 
enzyme, indicating that it plays a role in the au-
toinhibitory function of the C-terminal region (Janosik 
et al., 2001; Shan et al., 2001). Additionally, the 
mutant 414-551, lacking proposed CBS domains, is 
about five-fold more active than the wild-type enzy-
me in the absence of AdoMet (Oliveriusova et al., 
2002). In this study, the enzyme activity showed no 
significant difference between the wild-type and 3' 
deleted forms of the CBS gene in vitro. In contrast, 
the rAAV-hCBSfull injection was more efficient at 
generating biochemical and histological improvements 
in CBS-/- mice in vivo compared with the rAAV- 
hCBSdel injection. 
    In a previous study, CBS-deficient mice (CBS+/-) 
showed approximately 50% reduction of CBS mRNA 
and enzyme activity in the liver, and plasma homo-
cysteine levels were about two times higher, com-
pared with wild-type mice (Watanabe et al., 1995). 
Plasma concentrations of homocysteine decreased 
by 22 weeks of age in CBS+/- mice and wild-type 
mice; however, the difference in plasma homocy-
steine levels between wild-type mice and CBS+/- 
mice was observed by 44 weeks of age (Watanabe 
et al., 1995). Compared with this previous study, in 
the present study, CBS+/- mice had plasma homo-
cysteine concentrations two times higher than 
wild-type mice two weeks after birth and no diffe-
rence in homocysteine concentration between wild- 
type and heterozygous mice was observed at 12, 16 
or 22 weeks (7.8 M, 4.8 M, 5.8 M vs. 7.4 M, 6.3 
M, 7.7 M, respectively). The plasma homocysteine 
level in heterozygotes did not change after gene 
transfer. These results suggest that the CBS+/- mouse 
is not suitable for studying the efficiency of gene 
therapy for homocystinuria.
    In conclusion, our data show that rAAV-mediated 
gene therapy is a potential treatment for homocy-
stinuria because CBS gene transfer in CBS-/- mice 
prolonged their life span, decreased homocysteine 
levels in plasma, and the transferred CBS gene was 
expressed in the liver. These findings suggest that 
AAV-mediated gene transfer may be a useful thera-
peutic candidate for the treatment of homocystinuria. 
Additionally, a more suitable mouse model is needed 
for further investigation of therapeutic strategies for 
patients with homocystinuria.
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